Welcome to our dedicated page for Cantel Medical news (Ticker: CMD), a resource for investors and traders seeking the latest updates and insights on Cantel Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cantel Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cantel Medical's position in the market.
Cantel Medical Corp (NYSE: CMD) announced the hiring of Michael Drexel as Senior Vice President and Chief Technology Officer, effective October 1, 2020. Drexel, based in Plymouth, Minnesota, will lead the Global R&D team, focusing on enhancing customer value through product development and innovation. With over 25 years of experience, including roles at Fresenius Medical Care, he brings significant expertise in engineering and technical leadership. CEO George Fotiades expressed enthusiasm for Drexel's proven track record in driving continuous improvement in technology teams.
Cantel Medical Corp. (CMD) reported its financial results for Q4 2020, showing net sales of $233.4M, a 2.5% decrease year-over-year. This decline was driven by an 18.0% organic sales drop, partially offset by 15.7% growth from acquisitions. GAAP EPS plummeted 125.5% to $(0.05), influenced by COVID impacts and restructuring costs. Non-GAAP EPS fell 62.6% to $0.24. The company generated $44.0M in cash from operations and ended the quarter with $277.9M in cash and $1,113.4M in debt. Daily sales rates improved to 80%-85% of pre-COVID levels, but full recovery timing remains uncertain.
Cantel Medical Corp. (NYSE: CMD) will announce its fourth-quarter results for the period ending July 31, 2020, on September 17, 2020, before the market opens. A conference call will be held at 8:30 a.m. ET to discuss the results, with information on how to participate provided. The earnings call will feature a digital replay available until October 16, 2020, and an audio webcast on Cantel's website. The company, focused on infection prevention products, aims to enhance patient safety and care quality.
Cantel Medical Corp (NYSE:CMD) announced estimated revenues for the fiscal fourth quarter ending July 31, 2020, projecting between $230 million and $235 million. This represents a 2% sequential decline from the previous quarter and a 19% year-over-year decline on an organic basis. Despite these figures, daily sales rates in Medical and Dental segments showed improvement, with procedures expected to reach 80%-85% of pre-COVID levels. CEO George Fotiades expressed cautious optimism but warned that a full recovery could take longer than anticipated due to ongoing COVID-19 impacts.
Cantel Medical Corp. (NYSE: CMD) has appointed Peter Clifford as President and Chief Operating Officer. Previously the Executive Vice President and COO, Clifford has shown strong leadership, particularly during the COVID crisis. He will manage overall business operations and drive commercial results in line with Cantel 2.0 initiatives. With over 25 years of experience, including roles at IDEX Corporation and General Electric, Clifford holds an MBA and a BS in Accounting. CEO George Fotiades praised his contributions and advocacy for the company's core values.
